Introduction to ARISE 2024

The ARISE Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate research in the treatment of intracranial hemorrhage (ICH), intracranial atherosclerotic disease (ICAD), and cerebral venous diseases (CVD), to ultimately result in improved acute and elective management, treatment, and prevention. To achieve this goal, ARISE 2024 will:
  • Develop new approaches to overcome barriers impeding drug and device development
  • Identify, clarify, and communicate the implications of new research for cerebrovascular diseases

  • Publish the consensus recommendations of ARISE participants which address these concerns

  • Promote adoption of ARISE solutions by research, industry, clinical and government communities

Meet Stakeholders

Academia, Funding/Regulatory agencies, Industry

Change the future

Help improve acute stroke treatment, care, and prevention.

WHY ATTEND

The ARISE architecture encompasses 3 primary stakeholders involved in advancing research and practice for treating cerebrovascular disease: academia, comprising leading international physicians and scientists across relevant disciplines; industry, involving scientists and executives from private-sector pharmaceutical, device, and imaging companies; and regulatory institutions, consisting of executive managers, physicians, and scientists from esteemed organizations like the NIH and FDA.

LEARN MORE

ЕXPERT OPINIONS

SCIENTIFIC PROGRAM

INVITATION
ONLY

NETWORK

CORE ORGANIZERS

DISCOVER